NCT00004645View on ClinicalTrials.gov

Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone

PHASE3UnknownINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

January 31, 1995

Conditions
Acute Disseminated EncephalomyelitisDevic's SyndromeMarburg's Variant of Multiple SclerosisBalo's Concentric SclerosisAcute Transverse Myelitis
Interventions
PROCEDURE

Plasma exchange

Sponsors

Collaborators (1)

Mayo Clinic
All Listed Sponsors
collaborator

Mayo Clinic

OTHER

lead

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

NCT00004645 - Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone | Biotech Hunter | Biotech Hunter